MedTrace Logo

Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study

NCT01586858 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 67

Last updated 2017-10-27

No results posted yet for this study

Summary

Rituximab is the first drug approved by the United States Food and Drug Administration (FDA) for the treatment of patients with granulomatosis with polyangiitis (Wegener's granulomatosis) or microscopic polyangiitis. Because it is a relatively new medication, the long-term safety and efficacy of this drug is not yet clear. This study proposes to follow patients who were enrolled in the RAVE study to determine if treatment with rituximab influences long-term outcomes.

Conditions

  • Granulomatosis With Polyangiitis
  • Microscopic Polyangiitis

Interventions

OTHER

Observational

Observational study of subjects previously enrolled in the RAVE trial

Sponsors & Collaborators

  • University of Alabama at Birmingham

    collaborator OTHER

  • Boston University

    collaborator OTHER

  • Mayo Clinic

    collaborator OTHER

  • Duke University

    collaborator OTHER

  • The Cleveland Clinic

    collaborator OTHER

  • University Medical Center Groningen

    collaborator OTHER

  • Johns Hopkins University

    lead OTHER

Principal Investigators

  • Philip Seo, MD · Johns Hopkins University

Eligibility

Min Age
12 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2014-05-15
Completion
2014-05-15

Countries

  • United States
  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01586858 on ClinicalTrials.gov